Diamedica therapeutics inc. (DMAC)
CashFlow / Yearly
Dec'19Dec'18Dec'17
Cash flows from operating activities:
Net loss

-10,649

-5,734

-4,260

Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation

1,164

620

409

Amortization of discount on marketable securities

74

-

-

Non-cash lease expense

49

-

-

Depreciation

21

15

4

Change in fair value of warrant liability

-

39

-9

Changes in operating assets and liabilities:
Amounts receivable

43

700

27

Prepaid expenses

-322

308

-6

Deposits

-183

-

271

Accounts payable

-301

-30

-

Accrued liabilities

226

402

-

Accounts payable and accrued liabilities

-

-

248

Net cash used in operating activities

-9,102

-5,696

-3,900

Cash flows from investing activities:
Purchase of marketable securities

12,919

-

-

Maturities of marketable securities

9,000

-

-

Disposition of property and equipment, net

13

-

-

Purchase of property and equipment

2

50

22

Net cash used in investing activities

-3,908

-50

-22

Cash flows from financing activities:
Proceeds from issuance of common shares, net of offering costs

-

14,726

2,917

Proceeds from the exercise of stock options

75

43

7

Principal payments on finance lease obligations

5

-

-

Proceeds from issuance of common shares and warrants, net offering costs

-

5,840

-

Proceeds from the exercise of common share purchase warrants

-

607

615

Net cash provided by financing activities

70

21,216

3,539

Net decrease in cash and cash equivalents

-12,940

15,470

-383

Supplemental disclosure of cash flow information:
Cash paid for income taxes

26

80

-

Cash paid for interest

2

11

57

Supplemental disclosure of non-cash transactions:
Reclassification of warrant liability upon warrant exercise

-

123

-

Assets acquired under capital lease

-

24

-